ReviewAAPS PharmSciTech2026
Polymer Drug Conjugate: A Revolution in Drug Delivery.
Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymer-drug conjugates (PDCs) represent a remarkable advancement in modern medicine, leveraging the physicochemical properties of polymers to enhance the efficacy and safety of therapeutic agents. This comprehensive review explores the historical evolution, selection criteria, design, and synthesis of PDC, highlighting their transformative impact on drug delivery. The Introduction of biocompatible and biodegradable polymers has been a game-changer, allowing seamless integration with biological systems. We delve into the various polymer selection criteria, focusing on commonly used polymers such as Polyethylene glycol (PEG), Poly Lactic Glycolic Acid (PLGA), and chitosan, and the importance of biocompatibility and biodegradability. The design and synthesis of PDC involve sophisticated chemical and physical conjugation methods, emphasising cleavable and non-cleavable linkers and targeting moieties. We explore the drug-release mechanisms critical for achieving targeted and controlled drug delivery, including pH-sensitive, enzyme-triggered, and redox-sensitive mechanisms. The advantages of PDCs, including improved pharmacokinetics and pharmacodynamics, enhanced targeted delivery, and reduced toxicity, are discussed in detail. Despite their numerous benefits, PDC face challenges, such as stability issues, manufacturing scalability, and immunogenicity. This review addresses these limitations and suggests potential solutions. We also highlight recent advances and innovations in the field, including stimuli-responsive systems, nano PDC, and emerging trends in precision medicine. The applications of PDCs extend beyond cancer therapy, including antimicrobial drug delivery and treatments for cardiovascular and neurodegenerative diseases. Regulatory and commercial aspects are examined, with a focus on FDA-approved PDCs, challenges in clinical translation, and market trends. Future directions for PDCs include integrating Artificial intelligence into conjugate design, developing hybrid systems with other drug-delivery technologies, and advancing sustainable synthesis approaches.
Indexed as
Identifiers
41928043What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.